Merck Deferred Long Term Liab from 2010 to 2024

MRK Stock  USD 99.18  0.68  0.68%   
Merck Deferred Long Term Liabilities yearly trend continues to be quite stable with very little volatility. The value of Deferred Long Term Liabilities is projected to decrease to about 1.5 B. Deferred Long Term Liabilities is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. View All Fundamentals
 
Deferred Long Term Liabilities  
First Reported
2009-06-30
Previous Quarter
1.4 B
Current Value
996 M
Quarterly Volatility
5.4 B
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Merck financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Merck's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.8 B, Interest Expense of 1.2 B or Total Revenue of 32.4 B, as well as many indicators such as Price To Sales Ratio of 4.32, Dividend Yield of 0.0246 or PTB Ratio of 6.92. Merck financial statements analysis is a perfect complement when working with Merck Valuation or Volatility modules.
  
Check out the analysis of Merck Correlation against competitors.

Latest Merck's Deferred Long Term Liab Growth Pattern

Below is the plot of the Deferred Long Term Liab of Merck Company over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. Merck's Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Merck's overall financial position and show how it may be relating to other accounts over time.
Deferred Long Term Liab10 Years Trend
Slightly volatile
   Deferred Long Term Liab   
       Timeline  

Merck Deferred Long Term Liab Regression Statistics

Arithmetic Mean4,210,148,333
Geometric Mean0.00
Coefficient Of Variation123.65
Mean Deviation3,641,234,444
Median1,795,000,000
Standard Deviation5,206,047,351
Sample Variance27102929T
Range16.4B
R-Value(0.49)
Mean Square Error22250481.6T
R-Squared0.24
Significance0.07
Slope(567,528,304)
Total Sum of Squares379441006.2T

Merck Deferred Long Term Liab History

20241.5 B
20231.6 B
20221.8 B
20213.4 B
2020B
20191.5 B
20181.7 B

About Merck Financial Statements

Merck investors utilize fundamental indicators, such as Deferred Long Term Liab, to predict how Merck Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Deferred Long Term Liabilities1.6 B1.5 B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.33)
Dividend Share
3.04
Earnings Share
4.78
Revenue Per Share
24.931
Quarterly Revenue Growth
0.044
The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.